Prof Taïeb speaks with ecancer at ESMO 2016 about the improved patient outcomes following the addition of cetuximab, an EGFR inhibitor, to standard FOLFOX therapy for patients with full RAS and BRAF wild type.

This follows similar results for adding cetuximab to FOLFOX in RAS wildtype metastatic colorectal cancer, reported at the ESMO 18th World Congress on Gastrointestinal Cancer.

Prof Taïeb outlines the results of this trial, and considers what this might mean for patients depending on their tumour genotype, tumour location, and the suitability of similar combinations with panitumumab and bevacizumab.